(2-Methylbenzo[d]thiazol-5-yl)methanamine | 903630-23-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: (2-Methylbenzo[d]thiazol-5-yl)methanamine
• 英文别名: (2-methyl-1,3-benzothiazol-5-yl)methanamine
• CAS: 903630-23-9
• 化学式: C₉H₁₀N₂S
• 分子量: 178.258
• InChiKey: CUHHGVZNNNKBHJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  67.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-methylbenzo[d]thiazol-5-yl methanesulfonate 在 2-双环己基膦-2',6'-二甲氧基联苯 、 palladium diacetate 、 sodium carbonate 、 乙二胺 作用下， 以 1,4-二氧六环 、 丙醇 、 水 为溶剂， 反应 48.0h， 生成 (2-Methylbenzo[d]thiazol-5-yl)methanamine
  参考文献：
  名称：

  One-Pot Primary Aminomethylation of Aryl and Heteroaryl Halides with Sodium Phthalimidomethyltrifluoroborate

  摘要：

  A one-pot primary aminomethylation of aryl halides, triflates, mesylates, and tosylates via Suzuki-Miyaura cross-coupling reactions with sodium phthalimidomethyltrifluoroborate followed by deamidation with ethylenediamine is reported.

  DOI：

  10.1021/ol301037s

文献信息

• Heterobicyclic metalloprotease inhibitors
  申请人：Steeneck Christoph

  公开号：US20070155738A1

  公开（公告）日：2007-07-05

  The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
• Heterotricyclic metalloprotease inhibitors
  申请人：Gege Christian

  公开号：US20080207607A1

  公开（公告）日：2008-08-28

  The present invention relates generally to azatriocyclic containing pharmaceutical agents, and in particular, to azatricyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azatricyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.
• Heterobicyclic Metalloprotease Inhibitors
  申请人：STEENECK Christoph

  公开号：US20090312312A1

  公开（公告）日：2009-12-17

  The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
• Heterotricyclic Metalloprotease Inhibitors
  申请人：Gege Christian

  公开号：US20100087420A1

  公开（公告）日：2010-04-08

  The present invention relates generally to azatriocyclic containing pharmaceutical agents, and in particular, to azatricyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azatricyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.
• Spiroindoline Antiparasitic Derivatives
  申请人：ZOETIS SERVICES LLC

  公开号：US20160296499A1

  公开（公告）日：2016-10-13

  The invention describes novel spiropiperidines of Formula (1A), (1B), and (1C) stereoisomers thereof, veterinarily acceptable salts thereof, compositions thereof, processes for making, and their use in animals as an antiparasitic. The variables A, R 1 , R 2 , R 3 , R 4 , v, m, 5, and n are as described herein.